Andere talen CNS Pharmaceuticals, Inc.

Aandelen

CNSP

US18978H2013

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 23-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,21 ^USD	+5,47%		+0,72%	-83,46%

23/04	Transcript : CNS Pharmaceuticals, Inc. - Special Call
01/04	CNS Pharmaceuticals, Inc. rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

CNS Pharmaceuticals to Participate in the Virtual Investor Lunch Break, the CNSP Opportunity	23/04
CNS Pharmaceuticals to Present at Two Investor Conferences in April	02/04
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	01/04
CNS Pharmaceuticals, Inc. Approves the Appointments to its Board Committees	27/02
Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday on Caution Ahead of Fed Meeting, Tech Earnings	30/01
CNS Pharmaceuticals Announces Pricing of $4.0 Million Public Offering	30/01
CNS Pharmaceuticals Prices $4 Million Offering; Shares Fall Pre-Bell	30/01
Biotech Commercialization Leader, Amy Mahery, to Join CNS Pharmaceuticals Board of Directors	19/01
CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors	18/01
CNS Pharmaceuticals Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	18/01
CNS Pharmaceuticals, Inc. Achieves Completion of Planned Enrollment in Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme	17/01
CNS Pharmaceuticals : Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin - Form 8-K	18/12
CNS Pharmaceuticals, Inc. Announces Successful Interim Analysis of Efficacy and Safety Data in Potentially Pivotal Study of Berubicin	18/12
How CNS Pharmaceuticals Is Taking a Different Approach to Find a Treatment for Glioblastoma, a Cancer with a Poor Prognosis and No Cure	07/12
CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy	22/11
CNS Pharmaceuticals to Release Interim Data by the End of the Year for Potential Glioblastoma Drug Candidate	17/11
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study before Year End	16/11
CNS Pharmaceuticals : Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End - Form 8-K	15/11
CNS Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11
CNS Pharmaceuticals to Participate at the Virtual Investor Ask the CEO Conference	20-10-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen CNS Pharmaceuticals, Inc.

Aandelen

CNSP

US18978H2013

Andere talen

Filters